\n<\/p>\n
“The information we’re presenting at this yr’s ASCO mirror the breadth and depth of our oncology pipeline and our unwavering dedication to analysis that would remodel outcomes for sufferers going through most cancers,” mentioned Roopal Thakkar <\/span> , M.D., government vice chairman, analysis and improvement and chief scientific officer, AbbVie. “These shows underscore our management in driving scientific innovation to handle a few of the most urgent unmet wants in oncology right this moment by leveraging our modern platforms similar to ADCs.” <\/p>\n An oral presentation on investigational\u00a0telisotuzumab adizutecan (ABBV-400, Temab-A), a next-generation, c-Met directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) payload, will showcase: <\/p>\n Temab-A can be being evaluated in a number of ongoing medical trials <\/a> together with a Section 1\/2 Research ( NCT06772623 <\/a> ) in first-line NSCLC with out actionable\u00a0genomic alterations together with budigalimab (AbbVie’s investigational programmed cell loss of life 1 inhibitor), a Section 2 research ( NCT06107413 <\/a> ) in second-line metastatic colorectal most cancers (CRC) together with fluorouracil, folinic acid and bevacizumab, and a\u00a0Section 3 research ( NCT06614192 <\/a> ) as monotherapy in sufferers with c-Met overexpressing refractory metastatic\u00a0CRC. <\/p>\n<\/li>\n<\/ul>\n “The anti-tumor exercise of Temab-A in sufferers with pre-treated, superior EGFR-mutated non-squamous NSCLC is encouraging and helps additional exploration of this novel ADC on this setting,” mentioned Ross Camidge <\/span> , M.D.,\u00a0Ph.D, College of Colorado <\/span> Most cancers Middle, United States <\/span> and principal investigator of the trial. “Temab-A seems to have a manageable security profile and continues to indicate promising medical exercise in superior NSCLC, which is related to poor prognosis.” <\/p>\n Extra oral shows will spotlight new security and efficacy knowledge for ABBV-706, a SEZ6-directed ADC with a Top1i payload, and pivekimab sunirine\u00a0(PVEK), a novel ADC designed to focus on CD123: <\/p>\n This ongoing research ( NCT05599984 <\/a> ) is evaluating ABBV-706 as monotherapy, or together with budigalimab, carboplatin, or cisplatin, in sufferers with superior stable tumors expressing SEZ6, together with small-cell lung most cancers, NENs and high-grade Central Nervous System tumors. <\/p>\n<\/li>\n PVEK can be being evaluated in a Section 1\/2 research ( NCT04086264 <\/a> ) in R\/R and newly identified acute myeloid leukemia. <\/p>\n<\/li>\n<\/ul>\n “Over the previous few years, we have considerably expanded our ADC portfolio to analyze a broad vary of stable tumors and blood cancers, reflecting our deep dedication to reworking most cancers care by way of focused therapies and biomarker pushed approaches,” mentioned\u00a0Daejin Abidoye, M.D., vice chairman, therapeutic space head of stable tumors, AbbVie. “These outcomes spotlight the potential of our investigational medicines to supply a significant medical profit in a number of difficult-to-treat cancers, the place present therapy choices are restricted.” <\/p>\n Additional data on AbbVie medical trials is out there at https:\/\/www.clinicaltrials.gov\/ <\/a> . <\/p>\n Extra particulars on key shows at ASCO can be found under and the total ASCO Annual Assembly 2025 abstracts can be found right here <\/a> . <\/p>\n\n
\n